Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase

被引:39
|
作者
Cane, Patricia A. [1 ]
Green, Hannah
Fearnhill, Esther
Dunn, David
机构
[1] Hlth Protect Agcy, Ctr Infect, Salisbury SP4 0JG, Wilts, England
[2] MRC, Clin Trials Unit, London, England
基金
英国医学研究理事会;
关键词
accessory mutations; HIV drug resistance; reverse transcriptase inhibitors; viral fitness;
D O I
10.1097/QAD.0b013e3280129964
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To identify accessory mutations associated with high levels of resistance to reverse transcriptase inhibitors (RTI). Design: HIV pol sequences from routine resistance tests from over 3000 patients who were treatment experienced and infected with subtype B HIV-1 were analysed. Changes relative to the wild-type amino acid for codons 1-400 of reverse transcriptase were determined in two series: (i) samples showing the accumulation of thymidine analogue mutations (TAMs); and (ii) samples showing the accumulation of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations. Methods: Accessory mutations were identified as occurring in those codons in which there was a statistically significant association between the distribution of amino acids and the number of TAMs/NNRTI resistance mutations. Positions already established as drug resistance positions by the International AIDS Society - USA Panel were not included in this analysis. Results: Twenty-four positions were identified where accessory mutations were associated with the accumulation of TAMS (20, 35, 39, 43, 60, 83, 98, 101, 122, 135, 179, 196, 203, 208, 218, 223, 228, 284, 322, 356, 359, 360, 371 and 381). Likewise changes at 25 positions (6, 20, 35, 39, 43, 53, 68, 90, 98, 101, 122, 179, 200, 203, 208, 218, 221, 223, 228, 284, 318, 320, 348, 359 and 371) were associated with NNRTI mutations. The accumulation of accessory mutations correlated with increasing numbers of TAMS and NNRTI mutations. Conclusion: The development of high-level resistance to RTI is associated not only with the accumulation of recognized mutations but also with accessory mutations. (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:447 / 455
页数:9
相关论文
共 50 条
  • [11] HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors
    Spence, RA
    Anderson, KS
    Johnson, KA
    BIOCHEMISTRY, 1996, 35 (03) : 1054 - 1063
  • [12] Development of high-level resistance to DMP 266 requires multiple mutations in the reverse transcriptase gene
    Winslow, DL
    Garber, S
    Reid, C
    Scarnati, H
    Korant, B
    Emini, E
    Anton, ED
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 13 - 13
  • [13] MUTATIONS IN THE C-TERMINAL REGION OF THE HIV-1 REVERSE TRANSCRIPTASE AND THEIR CORRELATION WITH DRUG RESISTANCE ASSOCIATED MUTATIONS AND ANTIVIRAL TREATMENT
    Michels, I.
    Staszewski, S.
    Guettler, L.
    Nisius, G.
    Mueller, A.
    Locher, L.
    Doerr, H. -W.
    Stuermer, M.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (10) : 415 - 421
  • [14] Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients
    Ceccherini-Silberstein, F.
    Malet, I.
    Fabeni, L.
    Svicher, V.
    Gori, C.
    Dimonte, S.
    Bono, S.
    Artese, A.
    D'Arrigo, R.
    Katlama, C.
    Antinori, A.
    d'Arminio Montforte, A.
    Calvez, V.
    Marcelin, A. G.
    Perno, C. F.
    ANTIVIRAL THERAPY, 2007, 12 : S6 - S6
  • [15] Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment
    I Michels
    S Staszewski
    L Gürtler
    G Nisius
    A Müller
    L Locher
    H-W Doerr
    M Stürmer
    European Journal of Medical Research, 15
  • [16] Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients
    Ceccherini-Silberstein, F.
    Malet, I.
    Fabeni, L.
    Svicher, V.
    Gori, C.
    Dimonte, S.
    Bono, S.
    Artese, A.
    D'Arrigo, R.
    Katlama, C.
    Antinori, A.
    Monforte, A. d'Arminio
    Calvez, V.
    Marcelin, A. G.
    Perno, C. F.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S6 - S6
  • [17] Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing?
    Gotte, Matthias
    PLOS MEDICINE, 2007, 4 (12) : 1858 - 1861
  • [18] Phenotypic drug resistance patterns in subtype a HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations
    Eshleman, SH
    Jones, D
    Galovich, J
    Paxinos, EE
    Petropoulos, CJ
    Jackson, JB
    Parkin, N
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (03) : 289 - 293
  • [19] Mutations in HIV-1 RNase H domain confer high-level resistance to nucleoside reverse transcriptase inhibitors and provide novel insights into the mechanism of nucleotide excision-mediated drug resistance
    Nikolenko, GN
    Palmer, S
    Maldarelli, F
    Mellors, JW
    Coffin, JM
    Pathak, VK
    ANTIVIRAL THERAPY, 2004, 9 (04) : U35 - U36
  • [20] Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance
    Babrzadeh, Farbod
    Varghese, Vici
    Pacold, Mary
    Liu, Tommy F.
    Nyren, Pal
    Schiffer, Celia
    Fessel, W. Jeffrey
    Shafer, Robert W.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) : 414 - 418